IBI318

DRUG5 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Hunan Province Tumor Hospital

Conditions

Advanced Cutaneous Squamous Cell CarcinomaAdvanced MalignancyHepatocellular CarcinomaNon-Small Cell Lung CancerSmall Cell Lung Carcinoma

Phase 1

Study of IBI318 in Participants With Advanced Malignancies

CompletedNCT03875157

Innovent Biologics (Suzhou) Co. Ltd.Advanced Malignancy

Start: 2019-04-19End: 2023-02-16Updated: 2023-02-27

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

TerminatedNCT04611321

Innovent Biologics (Suzhou) Co. Ltd.Advanced Cutaneous Squamous Cell Carcinoma

Start: 2020-12-01End: 2023-03-10Updated: 2023-03-28

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

TerminatedNCT04635527

Innovent Biologics (Suzhou) Co. Ltd.Hepatocellular Carcinoma

Start: 2020-12-24End: 2023-03-07Updated: 2023-03-16

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

CompletedNCT04672928

Innovent Biologics (Suzhou) Co. Ltd.Small Cell Lung Carcinoma

Start: 2020-12-14End: 2023-01-31Updated: 2023-02-27

Phase 2

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.

RecruitingNCT04777084

Hunan Province Tumor HospitalNon-Small Cell Lung Cancer

Start: 2021-08-01End: 2025-12-25Target: 120Updated: 2025-03-05

Related Papers

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.

2025-12-15

Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors.

Journal of Clinical Oncology2020-05-206 citations